<div id="readability-page-1"><div>                     <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/travere-therapeutics-inc-logo-1200x675.png/query-dj0yMDI0MTEwNzEzNDU1Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/travere-therapeutics-inc-logo-1200x675.png/query-dj0yMDI0MTEwNzEzNDU1Mg"/>Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) Director Roy D. Baynes sold 16,000 shares of the firm's stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $20.00, for a total transaction of $320,000.00. Following the completion of the sale, the director now directly owns 31,000 shares in the company, valued at $620,000. This represents a 34.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link.</p><h2>Travere Therapeutics Stock Performance</h2><ul><li>3 Under-the-Radar Healthcare Companies</li></ul><p>NASDAQ:TVTX opened at $20.81 on Friday. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. Travere Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $20.89. The business has a 50 day moving average price of $18.28 and a 200-day moving average price of $14.79. </p><p>Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.01. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The business had revenue of $62.90 million during the quarter, compared to analysts' expectations of $60.87 million. During the same quarter in the prior year, the company posted ($1.17) EPS. The firm's revenue for the quarter was up 69.6% compared to the same quarter last year.  Equities analysts forecast that  Travere Therapeutics, Inc. will post -3.92 earnings per share for the current year. </p><h2>Analyst Upgrades and Downgrades</h2><hr/><hr/><br/><ul><li>Travere Therapeutics Still On The Rise After Encouraging Data </li></ul><p>A number of equities analysts have recently commented on TVTX shares. Wells Fargo &amp; Company raised shares of Travere Therapeutics from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and increased their price target for the stock from $9.00 to $27.00 in a report on Monday, October 21st. Piper Sandler increased their target price on Travere Therapeutics from $12.00 to $22.00 and gave the company a &#34;neutral&#34; rating in a research note on Thursday, November 14th. Canaccord Genuity Group dropped their price target on Travere Therapeutics from $23.00 to $22.00 and set a &#34;buy&#34; rating for the company in a research note on Monday, September 30th. Guggenheim increased their price objective on Travere Therapeutics from $23.00 to $41.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, October 9th. Finally, Cantor Fitzgerald started coverage on Travere Therapeutics in a research report on Friday, January 10th. They issued an &#34;overweight&#34; rating for the company. One research analyst  has rated the stock with a hold rating and twelve have assigned  a buy rating to the company's stock. According to data from MarketBeat, Travere Therapeutics  has an average rating of &#34;Moderate Buy&#34; and an average price target of $24.00.</p><p><b>Read Our Latest Stock Report on TVTX</b></p><h2>Institutional Trading of Travere Therapeutics</h2><p>Several large investors have recently modified their holdings of the business. Aigen Investment Management LP purchased a new stake in  Travere Therapeutics in the 3rd quarter worth approximately $170,000.  Oppenheimer &amp; Co. Inc. bought a new position in shares of  Travere Therapeutics during the third quarter valued at approximately $673,000.  Millennium Management LLC lifted its stake in  Travere Therapeutics by 33.9% in the second quarter. Millennium Management LLC now owns 2,949,335 shares of the company's stock worth $24,244,000 after acquiring an additional 747,406 shares during the period.  FMR LLC boosted its holdings in  Travere Therapeutics by 27.5% in the third quarter. FMR LLC now owns 147,416 shares of the company's stock valued at $2,062,000 after acquiring an additional 31,772 shares in the last quarter.  Finally, Two Sigma Advisers LP increased its position in  Travere Therapeutics by 30.2% during the 3rd quarter. Two Sigma Advisers LP now owns 720,400 shares of the company's stock valued at $10,078,000 after purchasing an additional 167,100 shares during the period. </p><h2>Travere Therapeutics Company Profile</h2><p> (Get Free Report)</p><p>Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.</p><h2>Read More</h2><ul><li>Five stocks we like better than Travere Therapeutics</li><li>Bank Stocks - Best Bank Stocks to Invest In</li><li>Market Momentum: 3 Stocks Poised for Significant Breakouts</li><li>Insider Buying Explained: What Investors Need to Know</li><li>Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming</li><li>Top Stocks Investing in 5G Technology</li><li>Momentum Builders: 3 Stocks Positioned to Shine This Quarter</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at Travere Therapeutics?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Travere Therapeutics and related companies.</p>                                                                       </div>                                                               <div>                         <div><p>More From MarketBeat</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/20241105123916_unnamed.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="512" height="345" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/20241105123916_unnamed.png"/></p><div><p>Vladimir Lenin was right…</p><p>The Magnificent 7 could be in for a world of pain…  And the insiders know it. It’s why Jeff Bezos just sold ...</p><p><span>Porter &amp; Company</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTEyOA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTEyOA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2059push_Depositphotos_647110414_S.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="250" height="154" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2059push_Depositphotos_647110414_S.jpg"/></p><div><p>7 Massive Growth Stocks to Own for the Next 10 Years</p><p> Many investors look to get in on the ground floor of a massive growth stock. For example, in 2024, a stock l...</p><p><span>MarketBeat</span></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2071push_AI_newer-8.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2071push_AI_newer-8.jpg"/></p><div><p>Most People Are Dead Wrong.</p><p>Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...</p><p><span>Brownstone Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTE2NQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTE2NQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2061push_Depositphotos_100691874_S.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="250" height="166" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2061push_Depositphotos_100691874_S.jpg"/></p><div><p>7 of the Best Long-Term Stocks to Buy</p><p>Despite the fact that Warren Buffett is one of its biggest proponents, buy-and-hold investing gets a bad rap a...</p><p><span>MarketBeat</span></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2060push_financial-newspaper-page-2654082_640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2060push_financial-newspaper-page-2654082_640.jpg"/></p><div><p>Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment</p><p>This isn't just another investment.  It might be the last retirement stock you'll ever need.  But this win...</p><p><span>Behind the Markets</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTExMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTExMQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2066push_Depositphotos_62486625_S.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="250" height="166" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2066push_Depositphotos_62486625_S.jpg"/></p><div><p>Betting on a Santa Claus Rally? Consider These 7 Risk-On Stocks</p><p>We're getting into the time of year when people start talking about a Santa Claus rally. Specifically, that's ...</p><p><span>MarketBeat</span></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2054push_RedGraph-5.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2054push_RedGraph-5.jpg"/></p><div><p>Please take this warning seriously...</p><p>I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...</p><p><span>Timothy Sykes</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTQ0Nw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTQ0Nw"/></p></div></div><div><p></p><div><p>The 10 Best Lithium Stocks to Buy for a Post Gasoline World</p><p>Electric vehicles currently make up about 5% of new car sales in the United States. While they have received a...</p><p><span>MarketBeat</span></p></div></div></div></div>                     </div>                 </div></div>

TVTX

<p>Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Roy D. Baynes sold 16,000 shares at $20.00 each, totaling $320,000, representing a 34.04% decrease in his ownership. Post-sale, he holds 31,000 shares valued at $620,000. The transaction was disclosed to the SEC. The company's stock opened at $20.81, with a 52-week range of $5.12 to $20.89. Recent earnings showed a revenue increase of 69.6% year-over-year, with analysts forecasting a negative EPS of -3.92 for the current year. Travere has received multiple upgrades from analysts, with an average price target of $24.00.</p>

Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Sells $320,000.00 in Stock